Development of an Industrial Reference Sample for the Specific Activity of Erythropoietin
- Autores: Yakovlev A.K.1, Volkova R.A.1, Simutenko L.V.1, Postnova E.L.1, Batuashvili T.A.1, Voropaev A.A.1, Alpatova N.A.1, Tomilin V.A.1, Mytsa E.D.1, Bondarev V.P.1, Merkulov V.A.1
-
Afiliações:
- Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
- Edição: Volume 52, Nº 1 (2018)
- Páginas: 90-94
- Seção: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245005
- DOI: https://doi.org/10.1007/s11094-018-1770-0
- ID: 245005
Citar
Resumo
On the basis of WHO recommendations and the principles developed for the standardization of erythropoietins we selected one epoetin alfa pharmaceutical substances included in the State Register of Medicines as a candidate reference sample. The results of the manufacturer’s monitoring of this pharmaceutical substance complied with the requirements of the normative documentation and additional verification of identity by capillary zone electrophoresis demonstrated the presence of eight isoforms, which corresponded to the requirements of the European Pharmacopeia. Conditions for the preparation of an industrial reference sample in lyophilized form were developed. The industrial reference sample was attested in interlaboratory tests and the value of the attested property - specific activity - was 2400 IU/ampule, with confidence limits of 94.5% to 105.8%. Studies of the stability of the industrial reference sample developed here gave a shelf life of five years at a storage temperature of -20°C, with potential to extend this on the basis of stability monitoring results.
Palavras-chave
Sobre autores
A. Yakovlev
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Autor responsável pela correspondência
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
R. Volkova
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
L. Simutenko
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
E. Postnova
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
T. Batuashvili
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
A. Voropaev
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
N. Alpatova
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
V. Tomilin
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
E. Mytsa
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
V. Bondarev
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
V. Merkulov
Scientific Center for Expert Assessment of Medicines, Ministry of Health of the Russian Federation
Email: YAK.Aleksey@gmail.com
Rússia, Building 2, 8 Petrovskii Boulevard, Moscow, 127051
Arquivos suplementares
